Posts by cowic

Agents: Radiotherapy Phase II Status  Closed, active Sponsor The Netherlands Cancer Institute   Further information: https://clinicaltrials.gov/ct2/show/NCT02106312   WHO is the trial for? Adult patients with confirmed Myxoid Liposarcoma (MLS) of the soft tissue without metastasis or with only a small number of metastasis (oligometastasis) Overall health status of the patient has to be good (ECOG…

Selinexor in Advanced Liposarcoma (SEAL) Agents: Selinexor Phase II/III Status  Closed, active Sponsor Karyopharm Therapeutics Inc   Further information: https://clinicaltrials.gov/ct2/show/NCT02606461    This is a randomized, multicenter, double-blind, placebo-controlled, Phase 2-3 study of patients diagnosed with advanced unresectable dedifferentiated liposarcoma (DDLS) WHO is the trial for? Patients of 12 years or older with confirmed DDLS Disease…

  Agents: DCC-2618 (Ripretinib) vs. Sunitinib Phase III Status  Closed for recruitment, active Sponsor Deciphera Pharmaceuticals LLC   Further information: https://clinicaltrials.gov/ct2/show/NCT03673501   WHO is the trial for? Patients with confirmed advanced or metastatic GIST Patients must have progressed on imatinib or are intolerant to imatinib; patients who had further lines of treatment after imatinib cannot…

This study evaluates the efficacy and safety of TRC105 in combination with pazopanib vs. pazopanib alone in advanced angiosarcomas. Trial name TAPPAS Agents TRC105 and pazopanib Phase III Status  Terminated Sponsor Tracon Pharmaceuticals Inc. A randomized phase III trial of TRC105 and pazopanib vs. pazopanib alone in patients with advanced angiosarcoma (TAPPAS).Further information: https://www.clinicaltrials.gov/ct2/show/study/NCT02979899?term=tracon&cond=Angiosarcoma&rank=1&show_locs=Y#locn  …

  Agents: DCC-2618 vs. placebo Phase III Status  Closed, active Sponsor Deciphera Pharmaceuticals LLC   Further information: https://clinicaltrials.gov/ct2/show/NCT03353753   WHO is the trial for? Patients with confirmed advanced or metastatic GIST with all types of mutation in KIT or PDGFRa (excluded are patients without KIT or PDGFRa mutations) Patients must have progressed on imatinib, sunitinib,…

Agents: Radiotherapy Phase II Status  Closed, active Sponsor The Netherlands Cancer Institute   Further information: https://clinicaltrials.gov/ct2/show/NCT02106312   WHO is the trial for? Adult patients with confirmed Myxoid Liposarcoma (MLS) of the soft tissue without metastasis or with only a small number of metastasis (oligometastasis) Overall health status of the patient has to be good (ECOG…

Trabectedin Maintenance post 1st-line in STS Agents: Trabectedin Phase III Status  Open, recruiting Sponsor EORTC in collaboration with PharmaMar  Further information: https://clinicaltrials.gov/ct/show/NCT02929394 or http://www.eortc.org/research_field/clinical-detail/1447/   Maintenance therapy with Trabectedin versus observation after first line treatment with doxorubicin of patients with advanced or metastatic soft tissue sarcoma WHO is the trial for? Adult patients (18 years…

ANITA – Nintedanib with Ifosfamide in advanced, metastatic Soft Tissue Sarcoma (STS) Agents: Nintedanib vs. Ifosfamide Phase II Status  Closed, active Sponsor EORTC in collaboration with Boehringer Ingelheim   Further information: https://clinicaltrials.gov/ct/show/NCT02808247 or http://www.eortc.org/research_field/clinical-detail/1506/     A Phase II study comparing Nintedanib with Ifosfamide in patients with advanced, metastatic Soft Tissue Sarcoma (STS) after failure…

NAVIGATOR: Avapritinib (BLU-285) Phase I study of Avapritinib (formerly BLU-285) in patients with GIST and other relapsed/refractory solid tumors (Navigator). Trial name: Navigator Agents: Avapritinib (formerly BLU-285) Phase I Status  Completed Sponsor Blueprint Medicines Corporation Further information: https://www.clinicaltrials.gov/ct2/show/NCT02508532?term=NCT02508532&rank=1 WHO is the trial for? Patients with GIST that has progressed following imatinib and at least 1…

Maintenance therapy with Cabozantinib in High Grade Uterine Sarcoma (HGUtS) Agents: Cabozantinib Phase II Status  Open, recruiting Sponsor EORTC   Further information: https://clinicaltrials.gov/ct/show/NCT01979393 or http://www.eortc.org/research_field/clinical-detail/62113/   A phase II study evaluating the role of maintenance therapy with Cabozantinib in High Grade Uterine Sarcoma (HGUtS) after stabilization or response to chemotherapy WHO is the trial for?…